Incidence, prevalence, and outcomes of systemic malignancy with bone metastases

Journal of Orthopaedic Surgery - Tập 28 Số 2 - Trang 230949902091598 - 2020
Wen‐Li Jiang1, Youlutuziayi Rixiati2, Bingqing Zhao3, Yongcheng Li4, Chuangang Tang5, Jun Liu6
1Department of Biochemistry and Molecular Biology, College of Basic Medical, Navy Medical University, Shanghai, China
2Department of Pathology, Soochow University Medical School, Suzhou, China
3Plastic and Aesthetic Department, Tianjin Third Central Hospital, Tianjin, China
4Department of Medical Oncology, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China
5Department of Breast Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China
6Department of Orthopedic Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China

Tóm tắt

Purpose: Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We collected patients diagnosed with solid malignant tumors deriving outside of the bone, hematologic malignancies, Kaposi sarcoma, lymphoma, and myeloma from the SEER database (from 2010 to 2013). The incidence, prevalence, and outcomes of these systemic malignancies with bone metastases were then analyzed. Results: A total of 67,605 patients with bone metastases at cancer diagnosis were included. The highest rate of bone metastases was observed in patients with small-cell lung cancer at the time of alternative primary site cancer diagnosis. Among 226,816 cases with metastatic disease, cases with breast cancer (65.58%), and prostate cancer (89.60%) had a high incidence proportion (>10%) of identified bone metastases. Patients with additional bone metastases resulting from prostate cancer, breast cancer, and testis cancer presented the best survival time. Conclusions: Incidence and prognosis differ considerably among bone metastases with different primary malignancy sites. These results may encourage appropriate application of bone imaging.

Từ khóa


Tài liệu tham khảo

10.3322/caac.21254

10.1186/1471-2407-11-492

10.4081/oncol.2017.321

10.3322/caac.21387

10.1016/j.clbc.2018.03.001

10.1007/s10555-017-9719-4

10.1097/SPC.0000000000000157

Jehn CF, 2016, Anticancer Res, 36, 2631

10.1634/theoncologist.12-1-20

10.1200/JCO.2013.49.6489

10.3390/ijms19041121

10.1158/1078-0432.CCR-06-0931

Clines GA, 2004, Clin Adv Hematol Oncol, 2, 295

10.1002/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3

10.1007/s00330-011-2221-4

10.1186/s12885-016-2047-1

10.1016/j.canep.2014.05.005

10.1097/MD.0000000000001063

Thông tin
Thông tin xuất bản

Journal of Orthopaedic Surgery

Tập 28 Số 2

230949902091598

Thông tin tác giả